Our study, along with these facts, indicates an excellent opportunity of using GHR-antagonists in melanoma therapy, which on one hand can potentially reduce tumor cell proliferation by targeting the increased GHR expression on tumor cells and also reduce circulating IGF1 levels by decreasing hepatic IGF1 output [111]. The gene discussed is GHR; the disease is melanoma.